Nitrogen Containing Patents (Class 514/459)
-
Publication number: 20030105158Abstract: Hydrates of the compound of formula (I) and crystalline forms thereof have excellent storage stability and are useful medicaments.Type: ApplicationFiled: October 24, 2002Publication date: June 5, 2003Applicant: SANKYO COMPANY, LIMITEDInventors: Masayuki Murakami, Masashi Watanabe, Makoto Yamaoka, Takeshi Honda
-
Patent number: 6566373Abstract: The invention relates to 3-hydroxy-and 3-keto-cyclohetero-substituted leucine compounds that are inhibitors of cysteine proteases, particularly cathepsin K, and are useful in the treatment of diseases in which inhibition of bone loss is a factor. The 3-hydroxy-or 3-keto-moiety is bonded to a tetrahydrothiophene, tetrahydrothiopyran, tetrahydrofuran or tetrahydropyran ring.Type: GrantFiled: July 30, 2001Date of Patent: May 20, 2003Assignees: SmithKline Beecham Corporation, SmithKline Beecham p.l.c.Inventors: Andrew D Gribble, Ashley Edward Fenwick, Robert W Marquis, Daniel F Veber, Jason Witherington
-
Publication number: 20030092759Abstract: Anticonvulsant derivatives useful for treating restless limb syndrome, more particularly restless legs syndrome, restless arms syndrome, periodic limb movement disorder and associated sleep disturbances, regardless of underlying cause.Type: ApplicationFiled: September 23, 2002Publication date: May 15, 2003Inventor: Faruk S. Abuzzahab
-
Publication number: 20030092637Abstract: The present invention relates to combinations of xylose compounds with other pharmaceutically active compounds, to pharmaceutical compositions comprising said combinations, as well as to use of these combinations for the manufacture of a medicament for treatment of proliferative disorders. In another aspect, the present invention relates to novel xylose compounds, to pharmaceutical compositions comprising said compounds, and to use of these compounds for the manufacture of a medicament or the treatment of proliferative disorders.Type: ApplicationFiled: October 15, 2002Publication date: May 15, 2003Inventors: Goran Magnusson, Pia Magnusson Hall, Mattias Belting, Niklas Falk, Lars-Ake Fransson, Katrin Mani
-
Publication number: 20030092730Abstract: Methods and compositions for modulating brain damage mediated by non-NMDA ionotropic glutamate receptor antagonists are provided. Methods for inhibiting neuronal cell damage and death in the brain following an injury (e.g., ischemic/hypoxic injury) and methods for inhibiting cell damage and death in conditions such as periventricular leukomalacia, cerebral palsy, mental retardation, and neonatal stroke, are also provided. These methods generally involve treating a subject with a non-NMDA ionotropic glutamate receptor antagonist. Pharmaceutical and packaged formulations that include non-NMDA ionotropic glutamate receptor antagonists are also provided.Type: ApplicationFiled: August 5, 2002Publication date: May 15, 2003Inventors: Frances E. Jensen, Joseph Volpe, Paul Rosenberg, Pamela L. Follett
-
Publication number: 20030092636Abstract: Co-therapy for the treatment and/or prevention of paraesthesia and/or dysesthesia comprising administering to a subject in need thereof a therapeutically effective amount of one or more anticonvulsant derivatives with potassium supplements.Type: ApplicationFiled: November 4, 2002Publication date: May 15, 2003Inventor: Stephen D. Silberstein
-
Patent number: 6562843Abstract: This invention provides novel substituted 3-pyridyl-4-arylpyrroles, and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by reducing TNF-&agr; production and/or p38 activity in appropriate cells. This invention also provides therapeutic and prophylactic methods using the instant pharmaceutical compositions.Type: GrantFiled: April 28, 2000Date of Patent: May 13, 2003Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventor: James L. Bullington
-
Publication number: 20030083370Abstract: The present invention provides a treatment for angiogenic diseases, including solid tumors. The treatment consists of administering therapeutically active dosages of FC101, resulting in a reduction in endothelial cell proliferation and inhibition of new blood vessel formation. FC101 can also be used as a lead compound to develop other pharmacologically-active compounds, by adding or substituting different functional groups for those already present on the FC101 molecule.Type: ApplicationFiled: August 2, 2002Publication date: May 1, 2003Inventors: Roy E. Wuthier, Daotai Nie
-
Patent number: 6555558Abstract: A microemulsion of pyranone protease inhibitor compounds that is substantially free of alcohol and propylene glycol comprising a pyranone protease inhibitor, one or more pharmaceutically acceptable surfactants, and a polyethylene glycol solvent having a mean molecular weight of greater than 300 but lower than 600, and a lipophilic component comprising medium chain mono- and di-glycerides, and optionally a basic amine.Type: GrantFiled: October 30, 2001Date of Patent: April 29, 2003Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Shirlynn Chen, Jocelyn A. Gunn
-
Publication number: 20030078213Abstract: A method for treating migraine in non-epileptic subjects which involves administering to subjects an effective amount of a pharmaceutical composition comprising a sulfamate of the following formula: 1Type: ApplicationFiled: September 25, 2002Publication date: April 24, 2003Applicant: New England Medical Center, a Massachusetts corporationInventors: Bruce L. Ehrenberg, Anita K. Wagner
-
Patent number: 6552000Abstract: Anticonvulsant derivatives useful in treating autism.Type: GrantFiled: January 18, 2000Date of Patent: April 22, 2003Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventor: Daniel P. Van Kammen
-
Publication number: 20030072802Abstract: The present invention is an improvement in the treatment of mania and depression by administering topiramate in a sustained-release formulation. The sustained-release formulation of the present invention may also be co-administered with anti-psychotics and anti-depressants.Type: ApplicationFiled: October 11, 2001Publication date: April 17, 2003Applicant: R.T. Alamo Ventures, Inc.Inventor: Neal R. Cutler
-
Patent number: 6545057Abstract: Methods and compositions of tricyclic antidepressants for inducing local long-lasting anesthesia and analgesia are provided. The methods and compositions are useful for alleviating acute and chronic pain, particularly useful for treating a localized pain.Type: GrantFiled: September 26, 2001Date of Patent: April 8, 2003Assignee: The Brigham and Women's Hospital Inc.Inventors: Ging Kuo Wang, Peter Gerner
-
Patent number: 6545022Abstract: Novel amines of formulas 1D and 1E are disclosed and are useful as agents in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, inflammatory diseases, and gastrointestinal disorders, especially IBS. Processes for the preparation and intermediates useful in the preparation are also disclosed.Type: GrantFiled: April 7, 2000Date of Patent: April 8, 2003Assignee: Pfizer Inc.Inventors: Justin Stephen Bryans, David Christopher Horwell, Clare Octavia Kneen, David Juergen Wustrow
-
Patent number: 6541509Abstract: The present invention concerns an unexpected synergistic combination of known antineoplastic agents which provides unexpectedly greater efficacy than the single agents alone. Accordingly, the present invention provides a method of treating neoplasia in a subject in need of treatment, by administering to the subject an amount of paclitaxel effective to treat the neoplasia, in combination with an amount of discodermolide effective to treat the neoplasia, wherein a synergistic antineoplastic effect results. The present invention further provides a synergistic combination of antineoplastic agents, comprising an effective antineoplastic amount of paclitaxel and an effective antineoplastic amount of discodermolide.Type: GrantFiled: September 14, 2001Date of Patent: April 1, 2003Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Susan B. Horwitz, Hayley M. McDaid, Laura A. Martello
-
Publication number: 20030060423Abstract: The present invention describes therapy for the treatment of dementia, memory disorders and the behavioral, psychiatric and/or psychological manifestations or symptoms associated with dementia or a memory disorder comprising co-therapy with a therapeutically effective amount of one or more acetylcholinesterase inhibitors with one or more anticonvulsant derivatives.Type: ApplicationFiled: August 28, 2002Publication date: March 27, 2003Inventor: Carlos R. Plata-Salaman
-
Publication number: 20030055008Abstract: Anticonvulsant derivatives useful in treating dementia and/or behavioral and psychotic disturbances in dementia are disclosed.Type: ApplicationFiled: May 13, 2002Publication date: March 20, 2003Inventor: David B. Marcotte
-
Patent number: 6534532Abstract: The invention concerns novel carbanilides of formula (I), in which A, Q, R, X, Z and m have the meanings given in the description. The invention further concerns a plurality of processes for preparing these substances, in their use as microbiocides for controlling undesirable microorganisms both in crop protection and in the protection of materials. Additionally, they are suitable for controlling animal pests.Type: GrantFiled: September 18, 2001Date of Patent: March 18, 2003Assignee: Bayer AktiengesellschaftInventors: Hans-Ludwig Elbe, Bernd-Wieland Krüger, Robert Markert, Ralf Tiemann, Dietmar Kuhnt, Stefan Dutzmann, Klaus Stenzel, Christoph Erdelen, Martin Kugler, Hans-Ulrich Buschhaus
-
Patent number: 6531139Abstract: The present invention provides a novel pharmaceutical composition based on the use of a particular oil phase which comprises a lipophilic, pharmaceutically active agent, a mixture of diglyceride and monoglyceride in a ratio of from about 9:1 to about 6:4 by weight (diglyceride:monoglyceride) wherein the diglyceride and monoglyceride are mono- or di- unsaturated fatty acid esters of glycerol having sixteen to twenty-two carbon chain length, one or more pharmaceutically acceptable solvents, and one or more pharmaceutically acceptable surfactants. The composition is in a form of self-emulsifying formulation which provides high concentration and high oral bioavailability for lipophilic compounds.Type: GrantFiled: July 27, 1998Date of Patent: March 11, 2003Assignee: Pharmacia & Upjohn CompanyInventors: Ping Gao, Walter Morozowich
-
Patent number: 6525182Abstract: Provided are reagents and methods useful for the synthesis of guanidinylated compounds. Also provided are methods for assaying molecules, including guanidinylated molecules that modulate viral infection and replication.Type: GrantFiled: January 22, 2001Date of Patent: February 25, 2003Assignee: Regents of the University of CaliforniaInventors: Murray Goodman, Yitzhak Tor, Tracy Baker, Nathan Luedtke
-
Patent number: 6518303Abstract: 2-Phenylpyran-4-one derivatives of formula (I): wherein: R1 represents an alkyl or —NR4R5 group, wherein R4 and R5 each independently represents a hydrogen atom or an alkyl group; R2 represents an alkyl, C3-C7 cycloalkyl, pyridyl, thienyl, naphthyl, tetrahydronaphthyl or indanyl group, or a phenyl group which may be unsubstituted or substituted by one or more halogen atoms or alkyl, trifluoromethyl, hydroxy, alkoxy, methylthio, amino, mono- or dialkylamino, hydroxalkyl or hydroxycarbonyl groups; R3 represents a methyl, hydroxymethyl, alkoxymethyl, C3-C7 cycloalkoxymethyl, benzyloxymethyl, hydroxycarbonyl, nitrile, trifluoromethyl or difluoromethyl group or a CH2—R6 group wherein R6 represents an alkyl group; and X represents a single bond, an oxygen atom, a sulfur atom or a methylene group; or pharmaceutically acceptable salts thereof, processes for their production and synthetic intermediates used in said processes, pharmaceutical compositions containing them and their useType: GrantFiled: March 16, 2001Date of Patent: February 11, 2003Assignee: Almirall Prodesfarma S.A.Inventors: Maria Isabel Crespo Crespo, Juan Miguel Jimenez Mayorga, Carles Puig Duran, Lidia Soca Pueyo
-
Patent number: 6518310Abstract: Aminoguanidine and alkoxyguanidine compounds, including compounds of the formula: wherein X is O or NR9 and R1-R4, R6-R9, R11, R12, Ra, Rb, Rc, Y, Z, n and m are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin are described. Also described are methods for preparing the compounds of Formula I. The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin, or are intermediates useful for forming compounds having antithrombotic activity.Type: GrantFiled: March 16, 2001Date of Patent: February 11, 2003Assignee: 3-Dimensional Pharmaceuticals, Inc.Inventors: Bruce E. Tomczuk, Richard M. Soll, Tianbao Lu, Cynthia L Fedde, Carl R Illig, Thomas P. Markotan, Thomas P Stagnaro
-
Patent number: 6503884Abstract: A method for treating migraine in non-epileptic subjects which involves administering to subjects an effective amount of a pharmaceutical composition comprising a sulfamate of the following formula:Type: GrantFiled: November 9, 1999Date of Patent: January 7, 2003Assignee: New England Medical Center Hospitals, Inc.Inventors: Bruce L. Ehrenberg, Anita K. Wagner
-
Publication number: 20030004117Abstract: Methods for inhibiting angiogensis are disclosed the comprise administering oleouropein and/or the products of its hydrolysis in therapeutically effective amounts. The methods and compositions of the present invention are particularly effective in inhibiting the vascularization of endothelial cells, and may be utilized to treat a wide variety of cancers, ocular diseases, and inflammatory conditions.Type: ApplicationFiled: May 22, 2002Publication date: January 2, 2003Inventors: Hamdi K. Hamdi, Jeffrey H. Tavis, Raquel Castellon
-
Patent number: 6495546Abstract: Propanolamine derivatives represented by the following formula (I): These derivatives may be &bgr;3 agonists and exert sympathomimetic, anti-ulcerous, anti-pancreatitis, lipolytic and anti-urinary incontinence and anti-pollakiuria activities. Pharmaceutical compositions containing such propanolamine derivatives, methods for the prevention and/or treatment diseases using these propanolamine derivatives, and processes for their preparation are also described.Type: GrantFiled: November 22, 2000Date of Patent: December 17, 2002Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Kiyoshi Taniguchi, Minoru Sakurai, Naoaki Fujii, Kumi Hosoi, Yasuyo Tomishima, Hisashi Takasugi, Hajime Sogabe, Hirofumi Ishikawa, Naomi Hanioka
-
Patent number: 6495523Abstract: Anticonvulsant compounds of the general formula I: where X, R1, R2, R3, R4, R5, and R6 are as herein defined; are useful in treating acute ischemia-induced neurodegeneration, such as occurs during and after stroke, head trauma, spinal injury, non-fatal cardiac arrest, or major surgical procedures. Furthermore, pharmaceutical compositions containing a compound of formula I as well as methods for their use are disclosed.Type: GrantFiled: July 20, 2000Date of Patent: December 17, 2002Assignee: Ortho McNeil-Pharmaceutical, Inc.Inventors: Michael J. Costanzo, Bruce E. Maryanoff, Richard P. Shank
-
Patent number: 6495594Abstract: The subject invention provides novel compositions of biologically active discodermolide compounds which can advantageously be used for immunomodulation and/or treating cancer. The compounds of the subject invention have utility for use in the treatment of cancer, as tubulin polymerizers and as microtubule stabilization agents. The present invention also pertains to the identification of regions of the discodermolide molecule which are responsible for certain aspects of the bioactivity of discodermolide compounds.Type: GrantFiled: February 28, 2001Date of Patent: December 17, 2002Assignee: Harbor Branch Oceanographic Institution, Inc.Inventors: Sarath P. Gunasekera, Ross E. Longley, Richard A. Isbrucker, Gopal K. Paul, Shirley A. Pomponi, Amy E. Wright
-
Publication number: 20020177723Abstract: 2,5-Diaryl tetrahydrofurans, 2,5-diaryl tetrahydrothiophenes, 2,4-diaryl tetrahydrofurans, 2,4-diaryl tetrahydrothiophenes, 1,3-diaryl cyclopentanes, 2,4-diaryl pyrrolidines, and 2,5-diaryl pyrrolidines are disclosed that reduce the chemotaxis and respiratory burst leading to the formation of damaging oxygen radicals of polymorphonuclear leukocytes during an inflammatory or immune response. The compounds exhibit this biological activity by acting as PAF receptor antagonists, by inhibiting the enzyme 5-lipoxygenase, or by exhibiting dual activity, i. e., by acting as both a PAF receptor antagonist and inhibitor of 5-lipoxygenase.Type: ApplicationFiled: April 11, 2000Publication date: November 28, 2002Inventors: Xiong Cai, Sajjat Hussoin, San-Bao Hwang, David Killian, T.Y. Shen
-
Patent number: 6486198Abstract: The application relates to the use of topiramate and related sulfamates for the treatment and/or prophylaxis of post traumatic stress disorder (PTSD).Type: GrantFiled: March 11, 2002Date of Patent: November 26, 2002Inventor: Jeffrey Berlant
-
Publication number: 20020173507Abstract: Selected novel urea compounds are effective for prophylaxis and treatment of diseases, such as cell proliferation or apoptosis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving stoke, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.Type: ApplicationFiled: August 14, 2001Publication date: November 21, 2002Inventors: Vincent Santora, Benny Askew, Arup Ghose, Andrew Hague, Tae Seong Kim, Ellen Laber, Aiwen Li, Brian Lian, Gang Liu, Mark Norman, Leon Smith, Andrew Tasker, Christopher Tegley, Kevin Yang
-
Patent number: 6482986Abstract: The invention concerns compounds of formula (I) wherein A, X, Y, n, R1, R2 and R3 are as defined in claim 1. Said compounds are specifically binding to sigma receptors particularly those of the peripheral nervous system.Type: GrantFiled: February 27, 2002Date of Patent: November 19, 2002Assignee: Sanofi-SynthelaboInventors: Robert Boigegrain, Bernard Bourrie, Martine Bourrie, Pierre Casellas, Jean Marc Herbert, Pierre Lair, Dino Nisato, Raymond Paul, Jean Claude Vernieres
-
Patent number: 6472370Abstract: Anticonvulsant derivatives useful in treating post traumatic stress disorder, are disclosed.Type: GrantFiled: October 12, 1999Date of Patent: October 29, 2002Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventor: Daniel P. Van Kammen
-
Publication number: 20020151524Abstract: The invention provides fungicidal compounds of formula I and salts thereof: 1Type: ApplicationFiled: August 6, 2001Publication date: October 17, 2002Applicant: Aventis CropScience S.A.Inventors: Vincent Gerusz, Darren James Mansfield, Joseph Perez, Jean-Pierre Vors
-
Patent number: 6465509Abstract: The invention encompasses the novel compounds of Formula I, which are useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions comprising compounds of Formula I as well as methods of treating cyclooxygenase-2 mediated diseases comprising administering to a patient in need of such treatment a non-toxic therapeutically effective amount of a compound of Formula I.Type: GrantFiled: June 27, 2001Date of Patent: October 15, 2002Assignee: Merck Frosst Canada & Co.Inventors: Chun-Sing Li, Cheuk Kun Lau, Michel Therien, Petpiboon Prasit
-
Publication number: 20020147157Abstract: Combination therapy comprising anti-diabetic agents and anticonvulsant derivatives useful for the treatment of Type II diabetes mellitus and Syndrome X are disclosed.Type: ApplicationFiled: October 25, 2001Publication date: October 10, 2002Inventor: Gregory S. Connor
-
Patent number: 6458827Abstract: A method of modifying or altering the structure of a 1&agr;-hydroxylated vitamin D compound to increase its biological activity by altering the conformational equilibrium of the A-ring to favor a chair conformation that presents the 1&agr;-hydroxyl in the axial orientation. This is accomplished by either locking the A-ring chair conformation in a geometry having an axially orientated 1&agr;-hydroxyl, or by the addition of one or more substituents to the A-ring which interact with other substituents in the molecule or on the A-ring to provide a driving force to the A-ring to adopt a chair conformation which presents the 1&agr;-hydroxyl in the axial orientation.Type: GrantFiled: July 20, 2001Date of Patent: October 1, 2002Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Rafal R. Sicinski
-
Patent number: 6458830Abstract: The present invention relates to compounds of the formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and n are defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis and postherpetic neuralgia.Type: GrantFiled: September 10, 2001Date of Patent: October 1, 2002Assignee: Merck Sharp & Dohme Ltd.Inventors: Simon Neil Owen, Eileen Mary Seward, Christopher John Swain, Brian John Williams
-
Patent number: 6458843Abstract: This invention is related to carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones represented by Formula I: or a pharmaceutically acceptable salt or prodrug thereof, wherein: Y is oxygen or sulfur; R1, R21, R22 and R23 are independently hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl, alkoxyalkyl or carboxyalkyl; or R22 and R23, together with the N, form a heterocycle; A1 and A2 are independently aryl, heteroaryl, saturated or partially unsaturated carbocycle or saturated or partially unsaturated heterocycle, any of which is optionally substituted; X is one or O, S, NR24, CR25R26, C(O), NR24C(O), C(O)NR24, SO, SO2 or a covalent bond; where R24, R25 and R26 are independently hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl, alkoxyalkyl or carboxyalkyl.Type: GrantFiled: October 21, 1999Date of Patent: October 1, 2002Assignee: Euro-Celtique S.A.Inventors: Yan Wang, Sui Xiong Cai, Nancy C. Lan, John F. W. Keana, Victor I. Ilyin, Eckard Weber
-
Publication number: 20020137791Abstract: Compounds of formula (I) or their salts or esters: 1Type: ApplicationFiled: October 3, 2001Publication date: September 26, 2002Applicant: SANKYO COMPANY, LIMITEDInventors: Takeshi Honda, Yoshiyuki Kobayashi, Makoto Yamashita
-
Patent number: 6455579Abstract: Disclosed are pyran derivatives, which have distinctive sensitivity to visible light and distinctive luminous ability. The derivatives are useful in photopolymerization, electroluminescence, and dye lasers, and are obtainable through a step of reacting a compound having a 4-cyanomethylene-2-methyl-4H-pyran skeleton with a compound having a 3-formylcoumarin skeleton.Type: GrantFiled: November 9, 2000Date of Patent: September 24, 2002Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku KenkyujoInventors: Makoto Satsuki, Akira Shinpo, Yasuyo Ooga, Sadaharu Suga, Atsushi Oda, Hiroshi Tada, Yoshikazu Sakaguchi
-
Patent number: 6451766Abstract: Compounds of formula (I) or their salts or esters: [wherein R1 is alkyl or haloalkyl; R2 and R3 each represents hydrogen or aliphatic acyl; X is hydroxy, halogen, alkoxy, or a group of formula RaO—, where Ra is aliphatic acyl; Y is a group of formula RbRcN— or RbRcN—O—, where Rb and Rc each is hydrogen or alkyl; and Z is oxygen or sulfur] have excellent sialidase inhibitory activity and are therefore useful for the treatment and prevention of influenza and other viral diseases where the replication of the virus is susceptible to sialidase inhibitors.Type: GrantFiled: October 3, 2001Date of Patent: September 17, 2002Assignee: Sankyo Company, LimitedInventors: Takeshi Honda, Yoshiyuki Kobayashi, Makoto Yamashita
-
Patent number: 6447809Abstract: A dietary supplement for benefitting human bone health includes a calcium source, a source of vitamin D activity, and an osteoblast stimulant. A preferred calcium source is microcrystalline hydroxyapatite, which also contains protein (mostly collagen), phosphorus, fat, and other minerals. A preferred source of vitamin D activity is cholecalciferol, and a preferred osteoblast stimulant is ipriflavone. In addition to these basic ingredients, the composition can further include various other minerals known to occur in bone, vitamin C, and glucosamine sulfate, all of which exert beneficial effects on growth and maintenance of healthy bone. A method for benefitting human bone health involves administering a daily regimen of the dietary supplement.Type: GrantFiled: May 11, 2000Date of Patent: September 10, 2002Assignee: Metagenics, Inc.Inventors: Kim C. Krumhar, Holly A. Johnson
-
Publication number: 20020123494Abstract: One embodiment of the present invention relates to acylaminoalkyl-substituted benzenesulfonamide derivatives of the formula (I), 1Type: ApplicationFiled: November 2, 2001Publication date: September 5, 2002Inventors: Holger Heitsch, Heinrich Christian Englert
-
Patent number: 6441026Abstract: A pharmaceutical composition comprised of acetocyclopropyl taxotere or a derivatve thereof, and at least one of an alkylating agent, an antimetabolite, a spindle poison, an epidophyllotoxin, an antibiotic, an enzyme, a topoisomerase inhibitor, a platinum coordination complex, a biological response modifier or a growth factor inhibitor is described.Type: GrantFiled: March 21, 2001Date of Patent: August 27, 2002Assignee: Aventis Pharma S.A.Inventor: Marie-Christine Bissery
-
Publication number: 20020111291Abstract: Disclosed is a class of compounds which inhibit the enzymatic conversion of fructose-lysine into fructose-lysine-3-phosphate in an ATP dependent reaction in a newly discovered metabolic pathway. According to the normal functioning on this pathway, fructose-lysine-3-phosphate (FL3P) is broken down to form free lysine, inorganic phosphate and 3-deoxyglucosone (3DG), the latter being a reactive protein modifying agent. 3DG can be detoxified by reduction to 3-deoxyfructose (3DF), or it can react with endogenous proteins to form advanced glycation end-product modified proteins (AGE-proteins), which are believed to be a contributing cause of diabetic complications. Also disclosed are therapeutic methods of using such inhibitors to reduce formation of AGE-proteins and thereby lessen, reduce and delay diabetic complications and the effects of glycogen storage diseases, including Fanconi's syndrome.Type: ApplicationFiled: October 10, 2001Publication date: August 15, 2002Inventors: Truman R. Brown, Francis Kappler
-
Publication number: 20020094960Abstract: Anticonvulsant derivatives useful for treating depression as monotherapy or combination therapy are disclosed.Type: ApplicationFiled: July 27, 2001Publication date: July 18, 2002Inventors: Carlos R. Plata-Salaman, Josue Bacaltchuk, Pedro A.S. Prado-Lima
-
Patent number: 6420369Abstract: Anticonvulsant derivatives useful in treating dementia and/or behavioral and psychotic disturbances in dementia are disclosed.Type: GrantFiled: May 15, 2000Date of Patent: July 16, 2002Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventor: David B. Marcotte
-
Patent number: 6417229Abstract: The present invention relates to a method of using a compound of the formula (I): wherein A, X1, X2 and Q are as defined herein, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, in the treatment of a disease, condition or disorder of the peripheral or central nervous system, including but not limited to Alzheimer's disease, stroke/cerebral ischemia, head trauma, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease, migraine, cerebral amyloid angiopathy, AIDS, age-related cognitive decline, mild cognitive impairment and prion diseases.Type: GrantFiled: September 27, 2000Date of Patent: July 9, 2002Assignee: Pfizer IncInventors: Barbara G. Sahagan, Anabella Villalobos
-
Patent number: 6413947Abstract: This invention is to provide a compound of the formula: wherein R1 is an optionally substituted 5- to 6-membered ring; W is a divalent group of the formula: wherein the ring A is an optionally substituted 5- to 6-membered aromatic ring, X is an optionally substituted C, N or O atom, and the ring B is an optionally substituted 5- to 7-membered ring; Z is a chemical bond or a divalent group; R2 is (1) an, optionally substituted amino group in which a nitrogen atom may form a quaternary ammonium, etc., or a salt thereof, which is useful for antagonizing MCP-1 receptor.Type: GrantFiled: September 13, 2000Date of Patent: July 2, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Mitsuru Shiraishi, Takahito Kitayoshi, Yoshio Aramaki, Susumu Honda, Tsuneo Oda
-
Publication number: 20020082222Abstract: The subject invention provides methods and compositions for the treatment of neurogenetic disorders, particularly DSM-IV impulse control disorders such as intermittent explosive disorder, kleptomania, pyromania, pathologic gambling, trichotillomania, and other impulse control disorders such as compulsive buying and problematic Internet use. In a preferred embodiment, the subject invention provides methods for treating or controlling symptoms associated with ADHD or PWS comprising the administration of therapeutically effective amounts of compositions containing compounds of the formulas I-V. In another embodiment, the subject invention provides for methods of promoting wound healing comprising the administration of a therapeutically effective amount of a composition comprising the compounds of formulas I-V. Compositions may administered to a wound site via a salve, ointment, or as a component of a bandage or bioadhesive applied to the site of injury.Type: ApplicationFiled: November 30, 2001Publication date: June 27, 2002Inventors: Nathan Andrew Shapira, Mary Catherine Lessig, Daniel John Driscoll